NCT05918107View on ClinicalTrials.gov

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 13, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
MPM
Interventions
DRUG

PM8002

IV infusion

DRUG

Pemetrexed

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

Trial Locations (1)

Unknown

RECRUITING

Jilin Provincial Tumor Hospital, Changchun

Sponsors

Lead Sponsor

Biotheus Inc.
All Listed Sponsors
lead

Biotheus Inc.

INDUSTRY